Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access